679 results about "Liver disease" patented technology

The invention discloses a liver disease diagnosis and treatment strategy recommendation method based on a knowledge graph, a medium and equipment, and the method comprises the steps: collecting the basic information of a user, constructing a space-time correlated individual liver disease knowledge graph according to the basic information of the user, and enabling the knowledge graph to comprise a disease cause feature node, a pathology grading node, a complication early warning node and a treatment response node which are correlated with each other; inputting the individual hepatopathy knowledge graph into a hierarchical reinforcement learning model for joint reasoning, and outputting multiple groups of strategy options including an antiviral treatment scheme, a liver protection drug combination and a metabolic intervention measure; analyzing a topological propagation path of a complication early warning node through a complication prediction sub-model, and dynamically adjusting an initial candidate diagnosis and treatment strategy set; and updating the individual hepatopathy knowledge graph when obtaining the basic information of the new user. According to the method, multi-dimensional data fusion and dynamic strategy optimization of liver disease diagnosis and treatment are realized, and the accuracy and timeliness of a diagnosis and treatment scheme are remarkably improved.

The invention discloses a liver disease image recognition processing method based on multi-modal fusion, a medium and equipment. The method comprises the following steps: acquiring multi-modal medical data in a liver disease diagnosis process; performing cross-modal feature extraction on the multi-modal medical data to obtain blood flow-image associated features; constructing a physiologically constrained space-time alignment model according to the blood flow-image correlation features, and outputting a synchronous mapping relationship between the blood vessel geometric topology network and the blood flow dynamic parameters; inputting the synchronous mapping relation into a liver disease grading classifier to generate a liver disease grading prediction result; and according to a prediction result, generating output content of multi-modal data visualization and displaying the output content. According to the method, effective fusion and collaborative analysis of multi-modal medical data are realized, and the accuracy and clinical practicability of liver disease grading are further improved.

The invention relates to the technical field of medical image processing, and discloses a method for intelligently describing liver space-occupying lesion ultrasonic image content by using LLM. A liver ultrasonic image sequence, a patient historical medical record text and a blood biochemical index vector are obtained through a multi-modal data acquisition module, and features are extracted through a cross-modal contrast learning network to generate embedded vectors and align the embedded vectors. And inputting the aligned image embedding vector into a dynamic context sensing decoder, and generating a description text semantic mark sequence by using a layered multi-head attention mechanism. The confidence coefficient is evaluated through an uncertainty calibration module, and the text is optimized through a post-processing reordering mechanism when the confidence coefficient is lower than a threshold value. A real-time interaction optimization mechanism is further arranged, and the model is updated according to feedback of doctors. According to the method, multi-modal data are fused, description accuracy and reliability are improved, text quality is optimized, clinical requirements are met, and liver disease diagnosis is assisted.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

A method for quantitatively assessing fat of a liver is disclosed. The method comprises: obtaining measured ultrasound data comprising an ultrasound image of the liver and corresponding radio frequency (RF) data of the liver; identifying a field of interest (FOI) in the ultrasound image; determining, for each of a plurality of graphical elements that are within the FOI, values of one or more parameters of interest that are indirect measures of the fat in the liver using the RF data and a pre-defined relationship; and enabling assessment of the fat in the liver based on the determined values.

A method for performing classification of a severity of at least one liver disease from non-invasive radiographic images is disclosed. The method comprises: providing radiographic images of slices of an abdomen of a patient; pre-processing said radiographic images by: segmenting a liver and a spleen, thus achieving a spleen binary mask and a liver binary mask per slice, and normalizing said images with each other, thus achieving normalized radiographic images per slice; for each slice, from the liver binary mask and said normalized radiographic images, extracting a liver parameter; from at least one spleen binary mask, extracting a spleen parameter; and classifying, in function of both parameters and by help of a trained Machine Learning model, the severity of the at least one liver disease between one among a group of liver disease at early stage and a group of liver disease at advanced stage.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

A method for performing classification of the severity of at least one liver disease from non-invasive radiographic images is disclosed. The method includes: providing radiographic images of slices of the abdomen of a patient; pre-processing the radiographic images by: segmenting liver and spleen, thus achieving a spleen binary mask and a liver binary mask per slice, and normalizing the images with each other, thus achieving normalized radiographic images per slice; for each slice, from the liver binary mask and the normalized radiographic images, extracting a liver parameter; from at least one spleen binary mask, extracting a spleen parameter; and classifying, in function of both parameters and by help of a trained Machine Learning model, the severity of liver disease between one among a group of liver disease at early stage and a group of liver disease at advanced stage.

The invention discloses an application of probiotics in preparation of a medicine for preventing and / or treating cholestatic liver diseases. The probiotics are selected from one or more of plant lactobacillus Lp-G18, bifidobacterium longum subsp. Longum BL-G301, lactobacillus reuteri LR-G100 and lactobacillus johnsonii LJ-G55. Preferably, the cholestatic liver disease is primary biliary cholangitis.

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The utility model discloses a hepatopathy detection sampling device for infectious disease department, which comprises a needle cylinder, a piston connected with the inner wall of the needle cylinder in a sliding manner, a piston rod fixedly connected with one end of the piston, a needle head connected with an interface of the needle cylinder through a hose, and a placing rack for supporting the needle cylinder, the needle cylinder and the needle head are in butt joint through the hose, so that in the process that the driving rod is driven to move so as to achieve piston movement, the needle head can be prevented from generating large shaking due to the fact that the needle cylinder and the needle head are in flexible connection, and the needle head is prevented from being damaged. Pain of a patient caused by shaking of the needle head is avoided; and by arranging the propelling mechanism, the piston can be driven to move, and the movement of the piston is smoother and more stable, so that a patient feels more comfortable in the sampling process.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The present invention regards specific IBAT inhibitors useful in the prophylaxis and / or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1 / PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

In certain embodiments, a continuous analyte monitoring system is provided. The continuous analyte system includes one or more continuous analyte sensors configured to generate one or more sensor signals indicative of one or more analyte levels, and at least one sensor electronics module. The at least one sensor electronics module includes an analog to digital converter configured to receive the sensor signal and convert the sensor current into digital signals. The continuous analyte monitoring system further includes a wireless transceiver configured to transmit the digital signalsto a wireless communications device, one or more memories comprising executable instructions, and one or more processors. The one or more processors are configured to execute the executable instructions to convert the digital signals to a set of estimated analyte measurements indicative of the true analyte levels of the user, and generate therapy management guidance based on the estimated analyte measurements.

A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof is disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and tris(hydroxymethyl)aminomethane. The furosemide is present in the pharmaceutical composition at a concentration from about 10 mg / mL to about 30 mg / mL and the tris(hydroxymethyl)aminomethane is present at a concentration of less than or equal to 40 mM. The pH value of the pharmaceutical composition is maintained between about 8.0 and about 8.5 for parenteral administration.

The present invention relates to novel lipid nanoparticles capable of liver-specific delivery of mRNA, a manufacturing method therefor, and a liver disease therapeutic agent capable of regenerating the liver by liver-specific delivery of the bio-reprogramming factor mRNA using same. The lipid nanoparticles according to the present invention allow for liver-specific delivery of mRNA at very high efficiency, and the lipid nanoparticles that encapsulate the mRNA-based bio-reprogramming factor mRNA are specifically delivered to liver tissues of an individual requiring liver regeneration to induce short-term expression, thereby easily setting the dose and expression period of a therapeutic agent, leading to a significant reduction in side effects of a therapeutic agent for liver regeneration using an existing cell reprogramming factor.

The invention discloses an application of a sugar chain marker combination in preparation of a product for identifying drug-induced liver injury and autoimmune hepatitis. The marker combination comprises a combination of more than one of the following N-sugar chain markers: NGA2F, NGA2FB, NG1A2F-1, NG1A2F-2, NA2, NA2F, NA2FB, NA3, NA3Fb, NA4 and NA4Fb; wherein the NG1A2F-1 and the NG1A2F-2 are in the form of an isomeride. According to the invention, non-invasive serum detection is adopted, so that the risk of invasive examination such as liver biopsy is avoided, and the kit has high detection rate and good clinical application value. According to the invention, early differential diagnosis of DILI and AIH can be realized, a new technical means is provided for accurate diagnosis and glycomics research of liver diseases, and the kit has important clinical significance and application potential.

The present invention relates to methods of treating metabolic dysfunction-associated steatohepatitis (MASH) in a human subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The present invention addresses the problem of providing: a method for preparing hepatic lineage cells in a large amount and with high purity; and a method for preparing liver system cells which can achieve high graft survival rate in a living body.　The present invention provides: a hepatoblast proliferation promoter and a culture medium, each of which contains a ROCK inhibitor, a TGFβ signaling pathway inhibitor, a Wnt signaling pathway activator, and a growth factor; and a proliferation / culture method using the hepatoblast proliferation promoter or the culture medium.

Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting CIDEB (e.g., hCIDEB); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing CIDEB expression (e.g., mRNA expression), methods of treating CIDEB associated diseases, and methods of treating liver diseases (e.g., MASH).

The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.

Disclosed is an ultrasonic imaging system including a probe configured to transmit an ultrasonic signal to an object including a liver and receive an ultrasonic echo signal reflected from the object, a display configured to display an ultrasonic image, an input interface configured to obtain user input, memory configured to store an artificial intelligence model, and at least one processor. The at least one processor is configured to obtain ultrasonic raw data by processing the ultrasonic echo signal, generate a plurality of raw image frames including different characteristic information by processing the ultrasonic raw data, obtain quantitative data about a liver disease from the artificial intelligence model by inputting the plurality of raw image frames into the artificial intelligence model, and display the ultrasonic image and the quantitative data about the liver disease together on the display.

Provided are methods of treating liver diseases comprising administering recombinant proteins comprising an interleukin-18-binding protein and an antigen binding fragment that binds to serum albumin.